| 1 |
Broglio KR, Quintana M, Foster M, et al. Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: A Meta-Analysis [J]. JAMA Oncol, 2016, 2(6): 751-760.
|
| 2 |
Von MG, Huang CS, Mano MS, et al. Trastuzumab Emtansine for residual invasive HER2-positive breast cancer [J]. N Engl J Med, 2019, 380(7): 617-628.
|
| 3 |
Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer [J]. J Clin Oncol, 2005, 23(16): 3676-3685.
|
| 4 |
Izumi Y, Xu L, Di TE, et al. Tumour biology: herceptin acts as an anti-angiogenic cocktail [J]. Nature, 2002, 416(6878): 279-280.
|
| 5 |
Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial [J]. Lancet Oncol, 2016, 17(6): 791-800.
|
| 6 |
Shao Z, Pang D, Yang H, et al. Efficacy, safety, and tolerability of Pertuzumab, Trastuzumab, and Docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: The PEONY phase 3 randomized clinical trial [J]. JAMA Oncol, 2019, 6(3): e193692.
|
| 7 |
Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial [J]. Lancet Oncol, 2018, 19(1): 115-126.
|
| 8 |
Hurvitz SA, Martin M, Jung KH, et al. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: Three-year outcomes from the phase III KRISTINE study [J]. J Clin Oncol, 2019, 37(25): 2206-2216.
|
| 9 |
Geyer JCE, Huang CS, Mano MS, et al. Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE [J]. Cancer Research, 2019, 79(4): GS1-10.
|
| 10 |
Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial [J]. Lancet, 2017, 389(10075): 1195-1205.
|
| 11 |
Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31 [J]. J Clin Oncol, 2011, 29(25): 3366-3373.
|
| 12 |
Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer [J]. N Engl J Med, 2011, 365(14): 1273-1283.
|
| 13 |
Tolaney SM, Guo H, Pernas S, et al. Seven-year follow-up analysis of adjuvant Paclitaxel and Trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer [J]. J Clin Oncol, 2019, 37(22): 1868-1875.
|
| 14 |
Piccart M, Procter M, Fumagalli D, et al. Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer [J]. Cancer Res, 2020, 80(4): GS1-04.
|
| 15 |
Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial [J]. Lancet Oncol, 2017, 18(12): 1688-1700.
|
| 16 |
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 [J]. N Engl J Med, 2001, 344(11): 783-792.
|
| 17 |
Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group [J]. J Clin Oncol, 2005, 23(19): 4265-4274.
|
| 18 |
Wardley AM, Pivot X, Morales-Vasquez F, et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer [J]. J Clin Oncol, 2010, 28(6): 976-983.
|
| 19 |
Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer [J]. N Engl J Med, 2015, 372(8): 724-734.
|
| 20 |
Zhou X, Cella D, Cameron D, et al. Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment [J]. Breast Cancer Res Treat, 2009, 117(3): 577-589.
|
| 21 |
Yan M, Bian L, Hu XC, et al. Pyrotinib plus capecitabine for human epidermal factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study [J]. Transl Breast Cabcer Res, 2020, 1(13): 18-30.
|
| 22 |
Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial [J]. Lancet Oncol, 2018, 19(12): E667-E667.
|
| 23 |
Modi S, Saura C, Yamashita T, et al. Trastuzumab Deruxtecan in previously treated HER2-positive breast cancer [J]. N Engl J Med, 2020, 382(7): 610-621.
|